MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease

    J. Yu, L. Saadatpour, H. Kaur, I. Mata, H. Fernandez (Cleveland, USA)

    Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…
  • 2023 International Congress

    Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration

    C. Gasca-Salas, P. Pineda-Pardo, M. Del álamo, T. Jiménez, C. Trompeta, L. García-Cañamaque, B. Fernández-Rodríguez, M. Matarazzo, I. Plaza Delasheras, E. Natera, R. Martínez-Fernández, S. Ruiz Deaguiar, J. Blesa, J. Obeso (Móstoles, Spain)

    Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…
  • 2023 International Congress

    Identification of pre-frailty in the elderly through serum metabolomics and its impact on Parkinson’s disease phenotype

    A. Imarisio, M. Avenali, G. Buongarzone, M. Picascia, T. Nuzzo, C. Gasparri, F. Errico, C. Marino, M. Grimaldi, MC. Monti, A. Filosa, M. Rondanelli, C. Pacchetti, AM. D'Ursi, A. Usiello, EM. Valente (Pavia, Italy)

    Objective: We attempted to better characterize pre-frailty using serum metabolomics in a large cohort of elderly subjects without neurodegenerative diseases. Next, we sought to investigate…
  • 2023 International Congress

    Relationship between sleep quality, fear of fall and falls history in people with Parkinson’s disease

    N. Alissa, R. Rehan, A. Al-Sharman, M. Sirine Latrous, A. Aburub, K. El-Salem, L. Morris, H. Khalil ()

    Objective: We aimed to investigate the relationship of sleep quality with falls and fear of fall (FOF) in people with Parkinson's disease (PwPD). Background: Fall…
  • 2023 International Congress

    Long term effects of Deep Brain Stimulation on Camptocormia in Parkinson’s disease

    L. Nessis, C. Oehlwein, M. Oehlwein, W J. Schulz-Schaeffer (Homburg

    Objective: Camptocormia (CC) as a syndrome often is a major burden for patients with Parkinson’s Disease (PD). In the absence of response to levodopa (except…
  • 2023 International Congress

    Comparative whole transcriptome analysis of human and mice models of Parkinson’s disease bearing defective glucocerebrosidase activity revealed alteration of expression profile of genes involved in the autophagy

    A. Bezrukova, K. Basharova, M. Rudenok, M. Nikolaev, A. Kopytova, I. Miliukhina, A. Emelyanov, M. Shadrina, P. Slominsky, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To identify potential biomarkers of Parkinson's disease (PD) associated with dysfunction of enzyme glucocerebrosidase (GCase) by a comparative whole transcriptome analysis of animal models…
  • 2023 International Congress

    Single-center experience of deep brain stimulation (DBS) surgery in Malaysia

    AM. Dy Closas, AH. Tan, JL. Lim, YW. Tay, A. Ahmad-Annuar, K. Lohmann, C. Klein, CY. Cham, KA. Muthusamy, SY. Lim (Kuala Lumpur, Malaysia)

    Objective: We aimed to characterize the DBS cohort and outcomes at a quaternary medical centre in Malaysia. Background: Deep brain stimulation s an established treatment…
  • 2023 International Congress

    Extent of cognitive impairment in Parkinson`s disease with Covid-19

    B. Muminov, E. Abduqodirov, R. Matmurodov, K. Khalimova (Tashkent, Uzbekistan)

    Objective: To study of the extent of cognitive impairment in PD patients with Covid-19. Background: Covid-19 may aggravate the clinical course of Parkinson's disease (PD)…
  • 2023 International Congress

    The cause of death in Parkinson’s disease

    K. Kamada, K. Kino, T. Takata (Kagawa, Japan)

    Objective: To investigate the causes of death in patients with Parkinson's disease at 6 hospitals in Kagawa Prefecture, Japan. Background: Not much literature exists on…
  • 2023 International Congress

    Long-term effects of a mobile technology-based brisk walking program on Parkinsonian symptoms in Parkinson’s disease – a randomized controlled trial

    MKY. Mak, ISK. Wong-Yu (Hong Kong SAR, China)

    Objective: To evaluate the effectiveness of a 6-month mobile technology-based brisk walking program on motor and non-motor symptoms and self-perceived ability in people with Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 100
  • 101
  • 102
  • 103
  • 104
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley